Current stock page

Financial Data

PVLA Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

PVLAPalvella Therapeutics, Inc.

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$152.48−$0.70 (−0.46%)

Latest quote

  • Momentum
    84
  • Value
    —
  • Quality
    65
  • Risk resilience
    47
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$0$0$0$0$0$0$0$0
Gross Profit$0$0$0$0$0$0$0$0
Operating Income-$22.73M-$21.41M-$14.86M-$11.3M-$10.18M-$9.25M-$7.87M-$4.37M
Net Income-$24.64M-$21.87M-$15.77M-$12.71M-$11.35M-$9.47M-$8.19M-$3.95M
EPS-$1.7-$1.52-$1.2-$1.08-$1.03-$0.86-$3.68-$0.88
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$14.43M-$12.85M-$10.86M-$4.93M-$7.88M-$5.43M-$6.77M-$5.39M
Capital Expenditure$0$0$0$0$0$0$0$0
Free Cash Flow-$14.43M-$12.85M-$10.86M-$4.93M-$7.88M-$5.43M-$6.77M-$5.39M
Net Cash Provided By Operating Activities-$14.43M-$12.85M-$10.86M-$4.93M-$7.88M-$5.43M-$6.77M-$5.39M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$239.4M$253.51M$263.76M$59.56M$66.94M$73.75M$79.44M$88.23M
Total Debt$485K$535K$584K$633K$16.02M$14.51M$0$0
Cash And Cash Equivalents$193.3M$187.8M$206.39M$57.98M$63.57M$70.43M$75.63M$83.6M
Total Liabilities$41.48M$36.58M$31.45M$31.58M$28.26M$25.97M$23.86M$25.63M
Total Stockholders Equity$197.92M$216.87M$232.31M$27.98M$38.68M$47.78M$55.58M$62.61M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio12.9210.066.3850.1223.3210.660.871
P/S ratio————————
Debt To Equity0000.020.410.300
Free Cash Flow Yield-1.68%-1.67%-1.96%-1.78%-2.82%———
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio12.9210.066.3850.1223.3210.660.871
P/S ratio————————
Return On Equity-37.89%-28.45%-21.22%-149.07%-85.19%-59.40%-41.53%-27.85%
Debt To Equity0000.020.410.300

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-27.72x
Pb11.2x
EPS Growth Yoy-65.05%
Gross Margin0.00%
Operating Margin0.00%
ROE-44.44%
ROIC-31.28%
Debt To Equity0
FCF Yield-1.93%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$152.48
Volume241,731
RSI (14)52.57
MACD6.84
MACD signal5.93
MACD histogram0.91
ADX (14)31.07
SMA (50)$143.56
SMA (200)$130.44
ATR (14)$9.63
Historical volatility (annualized)75.14%
Volume (20-day average)284,167

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score47/100
Beta1.65
Annual volatility84.47%
Max Drawdown-31.11%
Sharpe Ratio1.12
VaR (95%, 1-day)-6.92%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

PVLA Financial Data FAQ

What is Palvella Therapeutics, Inc.'s revenue?

Palvella Therapeutics, Inc.'s revenue is one of the core financial data points for PVLA. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Palvella Therapeutics, Inc.'s revenue growing?

Revenue growth shows whether Palvella Therapeutics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is PVLA's EPS?

PVLA's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Palvella Therapeutics, Inc.'s net income?

Palvella Therapeutics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Palvella Therapeutics, Inc. generate?

Free cash flow shows how much cash Palvella Therapeutics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Palvella Therapeutics, Inc. have?

Cash and debt help frame PVLA's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.